Amicus Therapeutics, Inc. or Vericel Corporation: Who Manages SG&A Costs Better?

SG&A Cost Management: Amicus Therapeutics vs. Vericel Corporation

In the competitive landscape of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and profitability. From 2014 to 2023, Amicus Therapeutics, Inc. and Vericel Corporation have shown distinct approaches to handling these costs. Amicus Therapeutics has seen a significant increase in SG&A expenses, rising from approximately $21 million in 2014 to $275 million in 2023, marking a staggering 1200% increase. In contrast, Vericel Corporation's SG&A expenses grew from about $14 million to $121 million over the same period, reflecting a more moderate increase of around 760%.

While both companies have expanded their SG&A budgets, Vericel's more controlled growth suggests a strategic approach to cost management. This comparison highlights the importance of balancing operational costs with business expansion, a critical factor for investors and stakeholders in the biotech sector.